Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE

FDA Approves Avanir’s Nuedexta

By Pharmaceutical Processing | November 1, 2010

The FDA has approved Avanir Pharmaceuticals’ drug for treating a
condition known as pseudobulbar effect — involuntary emotional outbursts
associated with brain disease or injury.

Its shares more than doubled in aftermarket trading, adding
$2.60 to $5.02. The stock had shed 39 cents, or nearly 14 percent, to $2.42
during the regular session.

The drug, dubbed Nuedexta, should be available by
prescription in the first quarter of next year, the company said.

“The approval of Nuedexta also marks Avanir’s
transition toward becoming a commercial enterprise, ready to support the
successful launch of the first FDA-approved treatment for (pseudobulbar
effect),” said Keith Katkin, Avanir’s president and chief executive.

In 2006, the FDA asked for more information on the drug to
consider it for approval. The company started an additional late-stage study on
a low-dose version of the drug in 2007 following an agreement with the agency
and submitted that data earlier this year.

 

 

 

 

Related Articles Read More >

Doctor, woman patient and tablet for consulting with results, medical info and talk for healthcare with mockup space. Japanese medic, digital touchscreen or show video for surgery, wellness or advice.
Putting patients first in clinical trials
Confidently navigate the transition from bench to batch
Merck
FDA approves Merck’s Winrevair to treat pulmonary arterial hypertension
kobayashi pharmaceutical logo
Report: Japan health authorities investigate Kobayashi Pharmaceutical factory after five deaths
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE